Last reviewed · How we verify
Bone Graft Placement
Bone Graft Placement is a Biologic drug developed by University of Michigan. It is currently FDA-approved for Bone defects and fractures requiring structural support, Spinal fusion procedures, Maxillofacial and dental bone reconstruction.
Bone graft placement provides structural support and biological scaffolding to promote bone regeneration and healing in skeletal defects.
Bone graft placement provides structural support and biological scaffolding to promote bone regeneration and healing in skeletal defects. Used for Bone defects and fractures requiring structural support, Spinal fusion procedures, Maxillofacial and dental bone reconstruction.
At a glance
| Generic name | Bone Graft Placement |
|---|---|
| Sponsor | University of Michigan |
| Modality | Biologic |
| Therapeutic area | Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Bone grafts serve as a framework for new bone formation by providing osteoconductive (supporting bone growth) and potentially osteoinductive (stimulating bone-forming cells) properties. The graft material fills bone voids, maintains space for new bone ingrowth, and may incorporate into the host bone over time through remodeling and resorption processes.
Approved indications
- Bone defects and fractures requiring structural support
- Spinal fusion procedures
- Maxillofacial and dental bone reconstruction
- Orthopedic trauma and reconstruction
Common side effects
- Graft site morbidity
- Infection
- Non-union or delayed union
- Graft resorption
Key clinical trials
- Using Different Biomaterials to Preserve Bone After Tooth Extraction (NA)
- Elamrousy Modified Approach for Socket Shield Technique (NA)
- Evaluation of the Magnesium Shield Compared to Dual Zone Grafting Approach in Immediate Implant Site Management. (NA)
- Elamrousy Novel Approach of Socket Shield Technique (NA)
- L-PRF Versus Sticky Bone Grafting of the Jumping Gap in AI-assisted Computer-Guided Socket Shield Immediate Implantation (NA)
- Anti-HLA Antibodies After Bone Regeneration Surgery (NA)
- Hard Tissue Augmentation With or Without Connective Tissue Graft in Immediate Esthetic Implants (NA)
- Adding 1% Metformin Gel to Bone Graft in Association With Immediate Dental Implants (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bone Graft Placement CI brief — competitive landscape report
- Bone Graft Placement updates RSS · CI watch RSS
- University of Michigan portfolio CI
Frequently asked questions about Bone Graft Placement
What is Bone Graft Placement?
How does Bone Graft Placement work?
What is Bone Graft Placement used for?
Who makes Bone Graft Placement?
What development phase is Bone Graft Placement in?
What are the side effects of Bone Graft Placement?
Related
- Manufacturer: University of Michigan — full pipeline
- Therapeutic area: All drugs in Orthopedics
- Indication: Drugs for Bone defects and fractures requiring structural support
- Indication: Drugs for Spinal fusion procedures
- Indication: Drugs for Maxillofacial and dental bone reconstruction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing